Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer

Award Number: R44DE024032
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/04/2014
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer - 7. Project Summary/Abstract This proposal supports the conduct of the clinical study IDR-OM-02 entitled, “A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Attenuation of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck”. This trial is designed to confirm the positive findings seen in the SBIR Phase I (R43DE024032) supported study IDR-OM-01 entitled “A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Multicenter Study of SGX942 for the Attenuation of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck”. Oral mucositis (OM) is a serious and debilitating condition and currently an unmet medical need for patients and physicians. It has a significant impact on patient quality of life and outcomes during cancer therapy as well as having a significant pharmacoeconomic cost. There are no currently approved drugs to treat OM in patients with non-hematological malignancies, including head and neck cancer (HNC). Severe OM (i.e., WHO grades 3 or 4) is the most clinically important form as they have the potential to result in alterations to a patient's cancer therapy. OM has been linked to the dysregulation of the innate defense system, resulting in an inflammatory cascade, which amplifies damage to the mucosal lining leading to clinically overt mucositis. Dusquetide (the active pharmaceutical ingredient in SGX942) is an Innate Defense Regulator (IDR), which binds to the p62 protein, a key adaptor protein which functions downstream of most innate immune receptors. SGX942 has received Fast Track Designation from the FDA validating it has demonstrated the potential to address this unmet medical need. SGX942 can address both acute trauma and acute infections, and SGX942 may have some independent direct anti-tumor activity via its activity in the innate immune system. This Phase II proposal seeks to conduct a study to confirm that SGX942 (1.5 mg/kg dusquetide) is an efficacious therapy for chemoradiation therapy (CRT) induced severe OM in patients with HNC, allowing for better long-term cancer-related outcomes. If successful, results from this study will support marketing authorization applications worldwide, including a New Drug Application (NDA) submission to the FDA. The Specific Aims of this proposal are: Specific Aim 1. Confirm the efficacy of 1.5 mg/kg SGX942 compared to placebo in reducing the duration of severe oral mucositis (SOM) in patients receiving CRT for their oral cavity or oropharyngeal squamous cell carcinoma. Specific Aim 2. Confirm the safety of this immunomodulator in HNC patients including the lack of interference with chemoradiation treatment outcomes (tumor progression and mortality) and the lack of an increased infection rate with 1.5 mg/kg SGX942 treatment compared to placebo.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2018	SOLIGENIX, INC.	29 EMMONS DR STE B10	PRINCETON	NJ	08540	MERCER	USA	Oral Diseases and Disorders Research	000	3	9/25/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $750,000 )
2018	2018	SOLIGENIX, INC.	29 EMMONS DR STE B10	PRINCETON	NJ	08540	MERCER	USA	Oral Diseases and Disorders Research	000	3	8/24/2018	NON-COMPETING CONTINUATION	$750,000
														Subtotal = $750,000

Issue Date FY: 2017 ( Subtotal = $714,817 )
2017	2017	SOLIGENIX, INC.	29 EMMONS DR STE C10	PRINCETON	NJ	08540	MERCER	USA	Oral Diseases and Disorders Research	000	2	9/13/2017	COMPETING CONTINUATION	$714,260
2017	2017	SOLIGENIX, INC.	29 EMMONS DR STE C10	PRINCETON	NJ	08540	MERCER	USA	Oral Diseases and Disorders Research	001	2	9/25/2017	COMPETING CONTINUATION	$557
														Subtotal = $714,817

Grand Total All Awards = $1,464,817

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer

Award Number: R44DE024032

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/04/2014

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer